OraSure Technologies (NASDAQ:OSUR) Announces Quarterly Earnings Results

OraSure Technologies (NASDAQ:OSUR) released its quarterly earnings data on Monday. The medical instruments supplier reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.05, FiscalAI reports. The business had revenue of $30.91 million for the quarter, compared to the consensus estimate of $31.00 million. OraSure Technologies had a negative net margin of 43.70% and a negative return on equity of 19.09%.

OraSure Technologies Stock Up 2.6%

Shares of NASDAQ OSUR traded up $0.09 during midday trading on Monday, reaching $3.53. 744,341 shares of the stock were exchanged, compared to its average volume of 557,322. The firm has a market cap of $243.46 million, a price-to-earnings ratio of -5.12 and a beta of 1.08. OraSure Technologies has a twelve month low of $2.08 and a twelve month high of $4.58. The firm has a 50-day simple moving average of $3.73 and a two-hundred day simple moving average of $3.53.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on OSUR. Wall Street Zen raised shares of OraSure Technologies from a “sell” rating to a “hold” rating in a report on Monday, August 10th. Weiss Ratings restated a “sell (d-)” rating on shares of OraSure Technologies in a research report on Tuesday, September 1st. Craig Hallum raised shares of OraSure Technologies to a “strong-buy” rating in a report on Friday, October 23rd. Finally, Zacks Research raised OraSure Technologies to a “hold” rating in a research report on Friday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $3.00.

About OraSure Technologies

OraSure Technologies, Inc develops, manufactures and markets diagnostic products and specimen-collection technologies used by healthcare providers, laboratories, researchers and consumers. The company focuses on making testing more accessible through products that support decentralized, point-of-care and at-home testing, as well as laboratory-based molecular and diagnostic workflows.

Its portfolio has included the OraQuick line of rapid diagnostic tests, including oral-fluid tests for HIV and hepatitis C, along with other infectious-disease testing products.